Eurosurv. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 Decemb

[tetano]

• Noam Barda[SUP]1,2,3,*[/SUP] , Michal Canetti[SUP]4,5,*[/SUP] , Mayan Gilboa[SUP]4,5[/SUP] , Victoria Indenboim[SUP]5,6[/SUP] , Keren Asraf[SUP]5,7[/SUP] , Yael Weiss-Ottolenghi[SUP]4,5[/SUP] , Sharon Amit[SUP]5,8[/SUP] , Daniel Zibly[SUP]4[/SUP] , Ram Doolman[SUP]5,6[/SUP] , Ella Mendelson[SUP]5,7[/SUP] , Dror Harats[SUP]5,9[/SUP] , Laurence S. Freedman[SUP]10[/SUP] , Yitshak Kreiss[SUP]5,9[/SUP] , Yaniv Lustig[SUP]5,6[/SUP] , Gili Regev-Yochay[SUP]4,5[/SUP]

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27–1.97) in Spikevax and 1.16-fold (95% CI: 0.98–1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62–1.09) and Comirnaty (0.86; 95% CI: 0.65–1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13–0.62) and 0.51 (95% CI: 0.27–0.96), respectively.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.39.2200701#html_fulltext